Clinical Trial Results: Safety and Immunogenicity of an Epstein-Barr Virus (EBV) gp350-Ferritin Nanoparticle Vaccine in Healthy Adults [Phase 1]

View source ↗

Summary

Phase 1 trial evaluating safety and immunogenicity of an Epstein-Barr Virus gp350-Ferritin nanoparticle vaccine in healthy adults has completed with results pos…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Epstein-barr Virus Infection
• Infectious Mononucleosis

Drugs mentioned

• gp350-Ferritin Nanoparticle Vaccine (gp350-Ferritin nanoparticle EBV vaccine)

Snippet

Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) | Conditions: EBV, Epstein-Barr Virus Infection | Phase 1 | Status: COMPLETED | Results posted: 2026-07-22